Physician profile
Ryan Smith Hennessy
NPI 1891141974
$4,276.22
in general payments reported to CMS, 2019-2025
30 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $238 · 2021: $598 · 2022: $791 · 2023: $1,280 · 2024: $763 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,517.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $817.63 | 2021-2025 | |
| Lilly USA, LLC | $716.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $355.63 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $312.39 | 2019-2025 | |
| Novo Nordisk INC | $249.68 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $244.01 | 2021-2025 | Farxiga, Bevespi Aerosphere, Airsupra |
| Pfizer INC. | $243.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.15 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $110.78 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Dexcom, INC. | $108.70 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $107.44 | 2021-2025 | Proclaim, Freestyle Libre 3 |
| Astellas Pharma US INC | $89.78 | 2020-2025 | Veozah |
| Sanofi Pasteur INC. | $75.24 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.79 | 2021-2022 | |
| Amgen INC. | $59.32 | 2021-2025 | Otezla, Repatha, Otezla |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $56.26 | 2023-2025 | |
| Axsome Therapeutics, INC. | $47.44 | 2022-2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $46.15 | 2022-2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.21 | 2022-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $40.91 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $40.85 | 2021-2023 | |
| Exact Sciences Corporation | $32.19 | 2023 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $30.33 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $28.64 | 2021 | |
| Ascensia Diabetes Care US INC. | $27.79 | 2025 | |
| Phathom Pharmaceuticals, INC. | $21.23 | 2024 | Voquezna |
| Tetraphase Pharmaceuticals, INC. | $18.95 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.10 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $12.81 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Hennessy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.